{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:53:38Z","timestamp":1790639618888,"version":"4.1.0"},"reference-count":77,"publisher":"American Society of Hematology","issue":"22","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,11,26]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>INCB053914 and ruxolitinib synergize to induce apoptosis of JAK2V617F-driven cells and to inhibit neoplastic growth of primary MPN cells. INCB053914 antagonizes ruxolitinib persistence in an in vivo MPN model.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000260","type":"journal-article","created":{"date-parts":[[2019,11,14]],"date-time":"2019-11-14T11:37:58Z","timestamp":1573731478000},"page":"3503-3514","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":32,"title":["The pan-PIM inhibitor INCB053914 displays potent synergy in combination with ruxolitinib in models of MPN"],"prefix":"10.1182","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8336-8032","authenticated-orcid":false,"given":"Lucia","family":"Mazzacurati","sequence":"first","affiliation":[{"name":"Department of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Collins","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0864-4137","authenticated-orcid":false,"given":"Garima","family":"Pandey","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8483-6312","authenticated-orcid":false,"given":"Que T.","family":"Lambert-Showers","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8672-5907","authenticated-orcid":false,"given":"Narmin E.","family":"Amin","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pathology and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Stubbs","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2228-8784","authenticated-orcid":false,"given":"Pearlie K.","family":"Epling-Burnette","sequence":"additional","affiliation":[{"name":"Department of Immunology, Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9745-3561","authenticated-orcid":false,"given":"Holly K.","family":"Koblish","sequence":"additional","affiliation":[{"name":"Incyte Corporation, Wilmington, DE; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-931X","authenticated-orcid":false,"given":"Gary W.","family":"Reuther","sequence":"additional","affiliation":[{"name":"Department of Molecular Oncology, Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2019,11,14]]},"reference":[{"key":"2019111521205812700_B1","doi-asserted-by":"crossref","first-page":"82","DOI":"10.12688\/f1000research.13167.1","article-title":"JAK inhibitors for the treatment of myeloproliferative neoplasms and other disorders","volume":"7","author":"Vainchenker","year":"2018","journal-title":"F1000 Res"},{"issue":"22","key":"2019111521205812700_B2","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2018-01-791491","article-title":"The role of JAK2 inhibitors in MPNs 7 years after approval","volume":"131","author":"Passamonti","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2019111521205812700_B3","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"8","key":"2019111521205812700_B4","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/leu.2016.148","article-title":"Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis","volume":"30","author":"Harrison","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"2019111521205812700_B5","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-017-0527-7","article-title":"Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2019111521205812700_B6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2019111521205812700_B7","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood-2013-12-544411","article-title":"Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts","volume":"123","author":"Passamonti","year":"2014","journal-title":"Blood"},{"issue":"6","key":"2019111521205812700_B8","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/blood-2012-02-414631","article-title":"Long-term outcomes of 107 patients with myelofibrosis receiving JAK1\/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls","volume":"120","author":"Verstovsek","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111521205812700_B9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/nrc2986","article-title":"For better or for worse: the role of Pim oncogenes in tumorigenesis","volume":"11","author":"Nawijn","year":"2011","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"2019111521205812700_B10","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4161\/cbt.8.9.8210","article-title":"PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells","volume":"8","author":"Zhang","year":"2009","journal-title":"Cancer Biol Ther"},{"issue":"6","key":"2019111521205812700_B11","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/j.molcel.2007.03.003","article-title":"PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase","volume":"25","author":"Sancak","year":"2007","journal-title":"Mol Cell"},{"issue":"1-3","key":"2019111521205812700_B12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.febslet.2004.06.050","article-title":"Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site","volume":"571","author":"Aho","year":"2004","journal-title":"FEBS Lett"},{"issue":"15","key":"2019111521205812700_B13","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1101\/gad.1105003","article-title":"The serine\/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor","volume":"17","author":"Fox","year":"2003","journal-title":"Genes Dev"},{"issue":"3","key":"2019111521205812700_B14","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrm3757","article-title":"Making new contacts: the mTOR network in metabolism and signalling crosstalk","volume":"15","author":"Shimobayashi","year":"2014","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2019111521205812700_B15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ceb.2017.02.012","article-title":"mTORC1 signaling and the metabolic control of cell growth","volume":"45","author":"Ben-Sahra","year":"2017","journal-title":"Curr Opin Cell Biol"},{"issue":"11","key":"2019111521205812700_B16","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.4213","article-title":"PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression","volume":"22","author":"Horiuchi","year":"2016","journal-title":"Nat Med"},{"issue":"10","key":"2019111521205812700_B17","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1158\/2159-8290.CD-16-0305","article-title":"Systematic functional characterization of resistance to PI3K inhibition in breast cancer","volume":"6","author":"Le","year":"2016","journal-title":"Cancer Discov"},{"issue":"3","key":"2019111521205812700_B18","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/1078-0432.CCR-18-0706","article-title":"Targeting PIM kinase with PD1 inhibition improves immunotherapeutic antitumor T-cell response","volume":"25","author":"Chatterjee","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111521205812700_B19","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.phrs.2013.01.005","article-title":"PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells","volume":"70","author":"Kim","year":"2013","journal-title":"Pharmacol Res"},{"issue":"4","key":"2019111521205812700_B20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1535-7163.MCT-17-0868","article-title":"PIM kinases are a potential prognostic biomarker and therapeutic target in neuroblastoma","volume":"17","author":"Brunen","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111521205812700_B21","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1158\/1078-0432.CCR-17-1629","article-title":"Concurrent inhibition of Pim and FLT3 kinases enhances apoptosis of FLT3-ITD acute myeloid leukemia cells through increased Mcl-1 proteasomal degradation","volume":"24","author":"Kapoor","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111521205812700_B22","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1038\/leu.2016.379","article-title":"Novel inhibition of PIM2 kinase has significant anti-tumor efficacy in multiple myeloma","volume":"31","author":"Nair","year":"2017","journal-title":"Leukemia"},{"issue":"18","key":"2019111521205812700_B23","doi-asserted-by":"crossref","first-page":"30199","DOI":"10.18632\/oncotarget.16320","article-title":"Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset","volume":"8","author":"Padi","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"2019111521205812700_B24","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1158\/1078-0432.CCR-16-0230","article-title":"The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care","volume":"23","author":"Pa\u00edno","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2019111521205812700_B25","doi-asserted-by":"crossref","first-page":"e1500221","DOI":"10.1126\/sciadv.1500221","article-title":"Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia","volume":"1","author":"Green","year":"2015","journal-title":"Sci Adv"},{"issue":"7","key":"2019111521205812700_B26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/bloodadvances.2018029850","article-title":"Hematopoietic cytokines mediate resistance to targeted therapy in FLT3-ITD acute myeloid leukemia","volume":"3","author":"Sung","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2019111521205812700_B27","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/stem.1369","article-title":"Pim1 serine\/threonine kinase regulates the number and functions of murine hematopoietic stem cells","volume":"31","author":"An","year":"2013","journal-title":"Stem Cells"},{"issue":"13","key":"2019111521205812700_B28","doi-asserted-by":"crossref","first-page":"6104","DOI":"10.1128\/MCB.24.13.6104-6115.2004","article-title":"Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors","volume":"24","author":"Mikkers","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"1","key":"2019111521205812700_B29","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1756-8722-6-12","article-title":"Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice","volume":"6","author":"An","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2019111521205812700_B30","doi-asserted-by":"crossref","first-page":"6130","DOI":"10.1074\/jbc.M409123200","article-title":"Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase","volume":"280","author":"Qian","year":"2005","journal-title":"J Biol Chem"},{"issue":"6","key":"2019111521205812700_B31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3324\/haematol.2009.017079","article-title":"PIM serine\/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers","volume":"95","author":"Brault","year":"2010","journal-title":"Haematologica"},{"issue":"2","key":"2019111521205812700_B32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4161\/jkst.20296","article-title":"JAK-STAT signaling in cardiomyogenesis of cardiac stem cells","volume":"1","author":"Mohri","year":"2012","journal-title":"JAK-STAT"},{"issue":"17","key":"2019111521205812700_B33","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1093\/emboj\/18.17.4754","article-title":"STAT5 as a molecular regulator of proliferation, differentiation and apoptosis in hematopoietic cells","volume":"18","author":"Nosaka","year":"1999","journal-title":"EMBO J"},{"issue":"6","key":"2019111521205812700_B34","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1074-7613(00)80145-4","article-title":"Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis","volume":"11","author":"Shirogane","year":"1999","journal-title":"Immunity"},{"issue":"47","key":"2019111521205812700_B35","doi-asserted-by":"crossref","first-page":"32334","DOI":"10.1074\/jbc.M803813200","article-title":"Effects of the JAK2 inhibitor, AZ960, on Pim\/BAD\/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2","volume":"283","author":"Gozgit","year":"2008","journal-title":"J Biol Chem"},{"issue":"37","key":"2019111521205812700_B36","doi-asserted-by":"crossref","first-page":"40141","DOI":"10.18632\/oncotarget.5653","article-title":"The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells","volume":"6","author":"Mazzacurati","year":"2015","journal-title":"Oncotarget"},{"issue":"10","key":"2019111521205812700_B37","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.18632\/oncotarget.1951","article-title":"Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance","volume":"5","author":"Huang","year":"2014","journal-title":"Oncotarget"},{"issue":"22","key":"2019111521205812700_B38","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.634.634","article-title":"Synergistic therapeutic efficacy of combined JAK1\/2, pan-PIM, and CDK4\/6 inhibition in myeloproliferative neoplasms [abstract]","volume":"128","author":"Rampal","year":"2016","journal-title":"Blood"},{"key":"2019111521205812700_B39","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-119421","article-title":"The PIM kinase inhibitor TP-3654 in combination with ruxolitinib exhibits marked improvement of myelofibrosis in murine models [abstract]","volume":"132","author":"Nath","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2019111521205812700_B40","doi-asserted-by":"crossref","first-page":"e0199108","DOI":"10.1371\/journal.pone.0199108","article-title":"Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies","volume":"13","author":"Koblish","year":"2018","journal-title":"PLoS One"},{"issue":"7","key":"2019111521205812700_B41","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1158\/1535-7163.MCT-10-0053","article-title":"Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805","volume":"9","author":"Baffert","year":"2010","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"2019111521205812700_B42","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"issue":"15","key":"2019111521205812700_B43","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111521205812700_B44","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","article-title":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia","volume":"123","author":"Keeton","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111521205812700_B45","doi-asserted-by":"crossref","first-page":"e54826","DOI":"10.1371\/journal.pone.0054826","article-title":"mTOR inhibitors alone and in combination with JAK2 inhibitors effectively inhibit cells of myeloproliferative neoplasms","volume":"8","author":"Bogani","year":"2013","journal-title":"PLoS One"},{"issue":"8","key":"2019111521205812700_B46","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"2019111521205812700_B47","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1172\/JCI98785","article-title":"Targeting compensatory MEK\/ERK activation increases JAK inhibitor efficacy in myeloproliferative neoplasms","volume":"130","author":"Stivala","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"2019111521205812700_B48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13045-014-0095-z","article-title":"Pim kinases in hematological malignancies: where are we now and where are we going?","volume":"7","author":"Mondello","year":"2014","journal-title":"J Hematol Oncol"},{"issue":"12","key":"2019111521205812700_B49","doi-asserted-by":"crossref","first-page":"3494","DOI":"10.1182\/blood.V85.12.3494.bloodjournal85123494","article-title":"Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor","volume":"85","author":"Yip-Schneider","year":"1995","journal-title":"Blood"},{"issue":"13","key":"2019111521205812700_B50","doi-asserted-by":"crossref","first-page":"6741","DOI":"10.1158\/0008-5472.CAN-05-4272","article-title":"Pim-3, a proto-oncogene with serine\/threonine kinase activity, is aberrantly expressed in human pancreatic cancer and phosphorylates bad to block bad-mediated apoptosis in human pancreatic cancer cell lines","volume":"66","author":"Li","year":"2006","journal-title":"Cancer Res"},{"issue":"46","key":"2019111521205812700_B51","doi-asserted-by":"crossref","first-page":"45358","DOI":"10.1074\/jbc.M307933200","article-title":"The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death","volume":"278","author":"Yan","year":"2003","journal-title":"J Biol Chem"},{"issue":"3","key":"2019111521205812700_B52","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.biocel.2005.10.010","article-title":"The oncogenic serine\/threonine kinase Pim-1 directly phosphorylates and activates the G2\/M specific phosphatase Cdc25C","volume":"38","author":"Bachmann","year":"2006","journal-title":"Int J Biochem Cell Biol"},{"issue":"4","key":"2019111521205812700_B53","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/0092-8674(89)90589-8","article-title":"Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors","volume":"56","author":"van Lohuizen","year":"1989","journal-title":"Cell"},{"issue":"2","key":"2019111521205812700_B54","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1128\/MCB.11.2.1176","article-title":"Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally","volume":"11","author":"Verbeek","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"9","key":"2019111521205812700_B55","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1158\/1541-7786.MCR-06-0388","article-title":"Pim-1 kinase-dependent phosphorylation of p21Cip1\/WAF1 regulates its stability and cellular localization in H1299 cells","volume":"5","author":"Zhang","year":"2007","journal-title":"Mol Cancer Res"},{"issue":"3","key":"2019111521205812700_B56","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/j.1460-2075.1989.tb03434.x","article-title":"Evidence for the involvement of pim-2, a new common proviral insertion site, in progression of lymphomas","volume":"8","author":"Breuer","year":"1989","journal-title":"EMBO J"},{"issue":"11","key":"2019111521205812700_B57","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/j.1460-2075.1995.tb07251.x","article-title":"Proviral tagging in E mu-myc transgenic mice lacking the Pim-1 proto-oncogene leads to compensatory activation of Pim-2","volume":"14","author":"van der Lugt","year":"1995","journal-title":"EMBO J"},{"issue":"5","key":"2019111521205812700_B58","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0092-8674(91)90382-9","article-title":"Identification of cooperating oncogenes in E mu-myc transgenic mice by provirus tagging","volume":"65","author":"van Lohuizen","year":"1991","journal-title":"Cell"},{"key":"2019111521205812700_B59","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.mce.2017.01.050","article-title":"JAK-STAT signaling in the therapeutic landscape of myeloproliferative neoplasms","volume":"451","author":"O\u2019Sullivan","year":"2017","journal-title":"Mol Cell Endocrinol"},{"issue":"6","key":"2019111521205812700_B60","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2019111521205812700_B61","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1158\/1078-0432.CCR-13-2062","article-title":"Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers","volume":"20","author":"Garcia","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2019111521205812700_B62","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1021\/jm800937p","article-title":"Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases","volume":"52","author":"Xia","year":"2009","journal-title":"J Med Chem"},{"issue":"4","key":"2019111521205812700_B63","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0092-8674(00)81382-3","article-title":"Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L)","volume":"87","author":"Zha","year":"1996","journal-title":"Cell"},{"issue":"357","key":"2019111521205812700_B64","doi-asserted-by":"crossref","first-page":"ra122","DOI":"10.1126\/scisignal.2005301","article-title":"RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis","volume":"7","author":"Winter","year":"2014","journal-title":"Sci Signal"},{"issue":"57","key":"2019111521205812700_B65","doi-asserted-by":"crossref","first-page":"96710","DOI":"10.18632\/oncotarget.18073","article-title":"Inhibitors of the PI3K\/mTOR pathway prevent STAT5 phosphorylation in JAK2V617F mutated cells through PP2A\/CIP2A axis","volume":"8","author":"Bartalucci","year":"2017","journal-title":"Oncotarget"},{"issue":"11","key":"2019111521205812700_B66","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/jcmm.12162","article-title":"Co-targeting the PI3K\/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms","volume":"17","author":"Bartalucci","year":"2013","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2019111521205812700_B67","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1158\/1535-7163.MCT-12-0862","article-title":"Dual PI3K\/AKT\/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells","volume":"12","author":"Fiskus","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"42","key":"2019111521205812700_B68","doi-asserted-by":"crossref","first-page":"26834","DOI":"10.18632\/oncotarget.25515","article-title":"Mechanisms for mTORC1 activation and synergistic induction of apoptosis by ruxolitinib and BH3 mimetics or autophagy inhibitors in JAK2-V617F-expressing leukemic cells including newly established PVTL-2","volume":"9","author":"Ishida","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"2019111521205812700_B69","doi-asserted-by":"crossref","first-page":"e84746","DOI":"10.1371\/journal.pone.0084746","article-title":"Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR\/p70S6K\/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera","volume":"9","author":"Nagao","year":"2014","journal-title":"PLoS One"},{"issue":"19","key":"2019111521205812700_B70","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1158\/1078-0432.CCR-18-4089","article-title":"Activation of JAK\/STAT signaling in megakaryocytes sustains myeloproliferation in vivo","volume":"25","author":"Woods","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2019111521205812700_B71","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/leu.2016.114","article-title":"JAK2V617F-mutant megakaryocytes contribute to hematopoietic stem\/progenitor cell expansion in a model of murine myeloproliferation","volume":"30","author":"Zhan","year":"2016","journal-title":"Leukemia"},{"issue":"11","key":"2019111521205812700_B72","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/stem.2888","article-title":"JAK2V617F megakaryocytes promote hematopoietic stem\/progenitor cell expansion in mice through thrombopoietin\/MPL signaling","volume":"36","author":"Zhang","year":"2018","journal-title":"Stem Cells"},{"issue":"17","key":"2019111521205812700_B73","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2019111521205812700_B74","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccr.2010.05.015","article-title":"Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells","volume":"17","author":"Mullally","year":"2010","journal-title":"Cancer Cell"},{"issue":"19","key":"2019111521205812700_B75","doi-asserted-by":"crossref","first-page":"6780","DOI":"10.1128\/MCB.23.19.6780-6789.2003","article-title":"Targeted disruption of the mouse PAS domain serine\/threonine kinase PASKIN","volume":"23","author":"Katschinski","year":"2003","journal-title":"Mol Cell Biol"},{"issue":"39","key":"2019111521205812700_B76","doi-asserted-by":"crossref","first-page":"15466","DOI":"10.1073\/pnas.0705407104","article-title":"PAS kinase is required for normal cellular energy balance","volume":"104","author":"Hao","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2019111521205812700_B77","doi-asserted-by":"crossref","first-page":"11091","DOI":"10.1038\/s41598-018-29234-8","article-title":"PAS kinase deficiency alters the glucokinase function and hepatic metabolism","volume":"8","author":"P\u00e9rez-Garc\u00eda","year":"2018","journal-title":"Sci Rep"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3503\/1506285\/advancesadv2019000260.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/3\/22\/3503\/1506285\/advancesadv2019000260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T23:48:52Z","timestamp":1573861732000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/3\/22\/3503\/422778\/The-panPIM-inhibitor-INCB053914-displays-potent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,14]]},"references-count":77,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019,11,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000260","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,14]]}}}